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Background: The aim of this study was to summarize the global predicting role of hormone receptors for survival
in endometrial cancer.
Methods: Eligible studies were identified and assessed for quality through multiple search strategies. Data were
collected from studies comparing overall survival (OS), cancer-specific survival (CSS), or progression-free survival
(PFS) in patients with elevated levels of estrogen receptor (ER), progesterone receptor (PR), or human epidermal
growth factor receptor 2 (HER2) with those in patients with lower levels. The combined hazard ratios of ER, PR, and
HER2 for survival were calculated.
Results: A total of 98 studies were included for meta-analysis (44 for ER, 38 for PR, and 16 for HER2). Higher
levels of either ER or PR could significantly indicate better survival. The pooled hazard ratios (HRs) of ER for
OS, CSS, and PFS were 0.75 (95 % CI, 0.68–0.83), 0.45 (95 % CI, 0.33–0.62), and 0.66 (95 % CI, 0.52–0.85),
respectively. The combined HRs of PR for OS, CSS, and PFS reached 0.63 (95 % CI, 0.56–0.71), 0.62 (95 % CI,
0.42–0.93), and 0.45 (95 % CI, 0.30–0.68), respectively. In contrast, elevated levels of HER2 could predict worse
outcome with a HR of 1.98 (95 % CI, 1.49–2.62) for OS, and a HR of 2.26 (95 % CI, 1.57–3.25) for PFS.
Conclusions: In patients with endometrial cancer, higher level of ER and PR predicted favorable survival,
and increased level of HER2 was associated with poorer survival. All of the three hormone receptors had
prognostic value for survival.
Keywords: Endometrial cancer, Estrogen receptor, Progesterone receptor, Human epidermal growth factor
receptor 2, PrognosisBackground
Endometrial cancer (EC) is the fourth most common
malignancy in women and the most common gyneco-
logic cancer [1], and in 2014, 52,630 new cases was diag-
nosed with an estimated 8590 deaths predicted in the
USA alone [2]. The incidence of EC is also increasing in
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creativecommons.org/publicdomain/zero/1.0/the 5-year survival rates for EC are approximately
78–90 % for stage I, 74 % for stage II, 36–57 % for stage
III, and 20 % for stage IV [5]. Additionally, women with
metastatic disease have only a median survival of 7–12
months [6]. Such poor outcomes raise an urgent require-
ment that more accurate prognosis and predictive markers
should be applied for EC to guide the therapy and monitor
the disease progress for individual patients.
Endometrial cancer is the most common genital tract
malignancy in women and consists of two major histo-
logical types, endometrioid endometrial cancer, and
non-endometrioid endometrial cancer including high-
risk malignancies such as serous papillary and clear cell
carcinoma. Endometrioid endometrial carcinoma is theticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Zhang et al. World Journal of Surgical Oncology  (2015) 13:208 Page 2 of 12most common form, accountable for more than 75–90 %
of all cases of endometrial cancer [7].
Besides conventional clinical or pathological features,
some biological molecules have been proposed as prog-
nostic biomarkers in EC, such as P53, KRAS, PTEN,
EGFR, FGFR, estrogen receptors (ER), progesterone re-
ceptors (PR), human epidermal growth factor receptor 2
(HER2), and so on [8]. Among them, hormone receptors
are attractive because of their physiological functions.
Through binding to their receptors, estrogen drives epi-
thelial proliferation, and progesterone inhibits growth
and causes cell differentiation. Interestingly, women who
ovulate and produce progesterone almost never get
endometrial cancer. Oppositely, disruption of the func-
tions of hormone receptors can lead to several types of
malignancies [9]. Due to higher response rates reported
for hormone receptor-positive tumors, these receptors
are currently considered to be important therapeutic tar-
gets and markers for the choice of treatment [10]. HER2
is a member of the human epidermal growth factor re-
ceptor tyrosine kinase family, which regulates many pro-
cesses that can promote tumor cell proliferation and
survival [11]. HER2 pathway, which may interact with
ER, is one of the most important pathways that have
been implicated in the development of endocrine resist-
ance in breast cancer. With the development of molecu-
lar biology and immunologic method, all of the three
hormone receptors have been introduced to refine out-
come prediction of female cancers, such as breast can-
cer, ovarian cancer, and endometrial cancer.
Our previous meta-analysis reported that higher level
of PR predicted favorable survival, and elevated level of
HER2 was associated with worse survival in ovarian can-
cer. Furthermore, ER-β may be a potentially strong pre-
dictor for better outcome [12]. A comparable situation
may also exist in research of EC, another malignant
tumor affected by the interaction between steroid hor-
mones and their respective receptors. Although a pile of
clinical studies on prognostic value of ER, PR, and HER2
expression levels in EC has also been done, no clear con-
clusion could be drawn to date. In 1985, Creasman et al.
reported that hormone receptor expression correlates
with disease-free survival in stages I and II endometrial
carcinoma [13]. However, inconsistent results were
obtained in the followed studies [14–17]. For example,
some studies showed that elevated levels of ER or PR
could significantly predict favorable outcome [18, 19],
whereas some other studies showed insignificant results
[20–22]. Moreover, some studies suggested that ele-
vated HER2 level was associated with poorer survival,
whereas other studies could not draw such significant
conclusion [20, 22].
Therefore, it is timely and necessary to analyze globally
the prognostic value of hormone receptors in a largerpopulation. In this study, we seek to conduct a meta-
analysis to evaluate the overall risk of hormone receptors
for endometrial cancer survival. We discussed endometrial
carcinoma and uterine papillary serous carcinoma in this
text.
Methods
We performed meta-analysis following the guidelines of
the Meta-analysis of Observational Studies in Epidemi-
ology group (MOOSE) [23].
Search strategy
We carefully searched online PubMed and EMBASE
from 1979 to May 2014 to identify relevant studies.
Three distinct sets of key words were used simultan-
eously in each set, namely, “estrogen receptor and endo-
metrial cancer prognosis,” “progesterone receptor and
endometrial cancer prognosis,” and “human epidermal
growth factor receptor 2 and endometrial cancer prog-
nosis.” Studies were considered eligible if they met the
following criteria: (1) they measured preoperative ER,
PR, or HER2 values; (2) they evaluated the potential
association between preoperative ER, PR, or HER2 levels
and the outcome of endometrial cancer; (3) their study
was retrospective or prospective in design; and (4) the
median period of follow-up was no shorter than 6
months. Articles were excluded based on the following
criteria: (1) review articles or letters, (2) non-English
articles, (3) laboratory studies, and (4) absence of key
information such as sample size, hazards ratio (HR),
95 %confidence interval (CI), and P value.
Titles, abstracts, full texts, and reference lists of all of
the identified reports were examined independently by
three reviewers (Zhang Y, Gong C, and Zhang F). These
extracted data have been double-checked by each other.
Disagreements were resolved by consensus between the
three readers or consultation with a fourth reviewer
(Zhao Y or Zhao D). In addition, a manual search was
conducted using references from the relevant literature,
including all of the identified studies, reviews, and edito-
rials. We e-mailed to the authors of studies for additional
information and the data needed for the meta-analytic
calculations. When duplicate studies were retrieved, we
included in our systematic review the study having re-
ported HRs or involving more patients (usually the latest).
This was performed to avoid overlapping between cohorts
and overestimation of the overall HR.
Quality assessment
According to a critical review checklist of the Dutch
Cochrane Centre proposed by MOOSE, we systematic-
ally assessed the quality of all the studies included [23].
The key points of the current checklist include (1) clear
definition of study population; (2) clear definition of
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such as overall survival (OS), cancer-specific survival
(CSS), disease-specific survival (DSS), progression-free
survival (PFS), disease-free survival (DFS), or recurrence-
free survival (RFS); and (4) sufficient period of follow-up.
If a study does not mention all four points, it was excluded
so as not to compromise the quality of the meta-analysis.
A flow diagram of the study selection process is presented
in Fig. 1.Fig. 1 Flow diagram of the study selection process. a ER studies.
b PR studies. c HER2 studiesData extraction and conversion
The extracted data elements of this review included (1)
publication details: first author’s last name, publication
year, and origin of the studied population; (2) study de-
sign; (3) characteristics of the studied population: sample
size, age, stage of disease, or histological type; and (4)
HR of elevated ER, PR, and HER2 for OS, CSS (includ-
ing DSS), and PFS (including DFS and RFS), as well as
their 95 % CI and P value. The simplest method con-
sisted in the direct collection of HR, odds ratio or risk
ratio, and their 95 % CI from the original article, with an
HR of less than 1 being associated with a better out-
come. If not available, the total numbers of observed
deaths/cancer recurrences and the numbers of patients
in each group were extracted to calculate HR .When
data were only available as Kaplan-Meier curves, data
were extracted from the graphical survival plots, and
estimation of the HR was then performed using the
described method.
Statistical analysis
A test of heterogeneity of combined HRs was conducted
using Cochran Q test and Higgins I-squared statistic. A
P value of less than 0.05 was considered significant. A
random-effect model (Der Simonian and Laird method)
was used if heterogeneity was observed (P < 0.05),
whereas the fixed-effect model was applied in the
absence of between-study heterogeneity (P < 0.05). Publi-
cation bias was evaluated using the funnel plot with the
Egger bias indicator test [24]. All analyses were con-
ducted using Stata: Data Analysis and Statistical Soft-
ware V10.1 (http://www.stata.com/).
Results and discussion
A total of 528 records for ER were identified from a pri-
mary literature search in PubMed and EMBASE. After
manually screening the titles, abstracts, and key data,
463 studies were excluded because they were review arti-
cles, letters, non-English articles, laboratory studies,
studies with important data missing, or studies irrelevant
to the current analysis. Of the 65 reports selected for de-
tailed evaluation, 1 study was excluded for being dupli-
cated; 20 others were excluded for lack of key data, such
as HR. The final meta-analysis was carried out for the
remaining 44 studies (n = 7119) for ER [13, 14, 16–18,
20–22, 25–61] (Fig. 1a). A similar identification process
was carried out in 425 studies for PR and 117 studies for
HER2. Finally, 38 studies recruiting 5502 patients for PR
[13, 14, 16–18, 20–22, 25, 26, 29, 31, 32, 34–43, 50–59,
61–65] (Fig. 1b) and 16 studies recruiting 1764 patients
for HER2 were included [20, 22, 33, 52, 54, 66–76]
(Fig. 1c). The main features of eligible studies are sum-
marized in Table 1. We collected data from Australia,
China, England, Finland, Germany, Greece, Italy, Japan,











Greece R EC 80 62.7 (48–82) OS SC 140
Backe 1997 [54] German R EC 124 68 (30–94) OS Reported 57.6 (0.24–180)
Borazjani 1989 [40] USA R EC 44 66 (36–86) OS SC 120
Chambers
1988-1 [51]
USA R EC 168 – OS DE 24 (1–118.8)
Covens 2011 [45] USA P EC 67 – OS, PFS SC 36
Creasman 1985 [13] USA R EC 168 63 (30–92) DFS DE 25 (1–74)
Engelsen 2008 [34] Norway R EC 230 – OS SC 192
Felix 2012 [28] USA R EC 199 – OS, RFS SC 42 (0.8–144)
Fukuda 1998 [14] Japan R EEC 92 60.3 (31–86) DFS, OS SC, reported 61.2 (0–174)
Gates 2006 [52] USA R EC 108 64.2 (27–95) OS DE 60
Gonzalez-Rodilla
2013 [20]
Spain R EC 126 65.9 (43–88) OS Report 70
Gul 2010 [31] Turkey R EC 49 58.3 (30–81) OS DE 24
Huvila 2013 [61] Finland R EEC 182 67 (35–93) DFS Reported 62.8 (4.2–84.4)
Ito 2005 [57] Japan R EEC 103 57 OS Reported 60 (2–148)
Jongen 2009 [17] Netherlands R EEC 315 64.7 (32–89) DSS, RFS,
OS
SC 59.6 (0–258)
Kadar 1993 [16] USA R EC 137 – OS DE 60
Kamat 2009 [32] USA R EEC 139 63 (27–91) DSS Reported 24.9
Kalogiannidis
2008 [35]
Greece R EC 77 62.5 (35–80) OS, CSS, DFS DE 60 (9–120)
Kauppila 1986 [42] Finland R EC 153 – DFS, OS SC 42 (12–96)
Krakstad
2012-primary [27]
Norway P EC 182 – DSS SC 60
Krakstad
2012-prospective [27]
Norway P EC 474 – DSS SC 60
Lenhard 2013 [59] German P EC 292 65.1 (35.6–88) OS Reported 13.8 (13.1–14.5)
Liao 1986 [43] USA R EC 75 – OS SC 50
Lindahl 1992 [50] Sweden R EC 298 63 (36–87) OS DE 60
Martin 1983 [44] Australia P EC 87 (48–85) OS SC (8–68)
Merritt 2010 [55] USA R EEC 85 63.4 (39–91) DSS Reported 72
Mhawech-Fauceglia
2013 [48]
USA R EC 316 – OS DE 60
Mylonas 2010 [30] Germany R EEC 214 65.1 (35–88) PFS, CSS, OS SC 96.3 (0.03–176.8)
Palmer 1988 [41] Australia R EC 351 64.5 (31–89) OS SC 100
Pertschuk 1996 [47] Caucasian,
Hispanic,
Oriental
R EC 78 65.5 (38–89) OS SC 37.5 (13–161)
Pradhan 2012 [26] Norwegian P UPSC 52 72 (56–89) OS, PFS DE 60
Saito 2006 [56] Japan R EEC 103 57 DFS, OS Reported 60 (2–148)
Rahman 2013 [18] Japan R EEC 111 60 (26–85) PFS, OS Reported 52 (5–139)
Salvesen 1998 [58] Norway P EC 97 65 (37–92) OS DE 108 (60–180)
Shabani 2007 [36] Germany R EC 293 64.8 (35.5–88) PFS, CSS, OS SC 89.6 (3.2–135.5)
Sho 2014 [60] Japan R UPSC 33 69.6 (55–82) CSS Reported 29 (2–174)
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Table 1 Summary table of the meta-analysis (Continued)
Singh 2007 [37] USA P EC 48 – OS Reported 19
Sivridis 2001 [38] Greece R EC 164 – OS SC 55 (19–167)
Song 2012 [29] Korea R EC 137 53.7 (30–82) OS Reported 60
Sun 2013 [46] China P EC 73 58 (30–78) DFS SC 43.4 (16–91)
Voss 2011 [22] England P EC 156 68.2 (37–89) DSS, RFS Reported 48.1 (0.1–141.5)
Wik 2013-R [49] Norway R EC 266 – DSS SC 300
Wik 2013-P [49] Norway P EC 153 – DSS SC 300
Zannoni 2013 [25] Italy P EEA 121 59 (35–88) DFS, OS Reported 38 (14–91)
Zhang 2013 [53] China R EC 239 54 (26–82) DFS, OS DE 67 (12–183)











Greece R EC 80 62.7 (48–82) OS SC 140
Backe 1997 [54] German R EC 197 68 (30–94) OS Reported 57.6 (0.2–180)
Borazjani 1989 [40] USA R EC 44 66 (36–86) OS SC 120
Chambers
1988-1 [51]
USA R EC 168 67 (49–90) OS DE 24 (1–118.8)
Creasman 1985 [13] USA R EC 105 63 (30–92) DFS DE 25 (1–74)
Ehrlich 1988 [65] USA R EC 174 56 (25–89) OS SC 27 (1–152)
Engelsen 2008 [34] Norway R EC 230 – OS Reported 192
Fukuda 1998 [14] Japan R EEC 92 60.3 (31–86) DFS SC 61.2 (0–174)
Gates 2006 [52] USA R EC 108 64.2 (27–95) OS Report 60
Gonzalez-Rodilla
2013 [20]
Spain R EC 126 65.9 (43–88) OS Reported 70
Gul 2010 [31] Turkey R EC 49 58.3 (30–81) OS DE 24
Huvila 2013 [61] Finland R EEC 182 67 (35–93) DFS Reported 62.8 (4.2–84.4)
Ito 2005 [57] Japan R EEC 103 57 DFS, OS Reported 60 (2–148)
Jongen 2009 [17] Netherlands R EEC 300 64.7 (32.0–89.0) DSS, RFS, OS SC, reported 59.6 (0–258)
Kadar 1993 [16] USA R EC 137 – OS DE 60
Kalogiannidis
2008 [35]
Greece R EC 77 62.5 (35–80) OS, CSS, DFS DE 60 (9–120)
Kamat 2009 [32] USA R EEC 139 63 (27–91) DSS report 24.9
Kauppila 1986 [42] Finland R EC 153 – DFS, OS SC 42 (12–96)
Liao 1986 [43] USA R EC 86 OS SC 50
Lenhard 2013 [59] German P EC 292 65.1 (35.6–88.1) OS Reported 13.8 (13.1–14.5)
Lindahl 1992 [50] Sweden R EC 272 63 (36–87) OS DE 60
Merritt 2010 [55] USA R EEC 85 63.4 (39–91) DSS Reported 72
Palmer 1988 [41] Australia R EC 351 64.5 (31–89) OS SC 100
Pradhan 2012 [26] Norwegian P SAC 50 72 (56–89) OS, PFS DE 60
Rahman 2013 [18] Japanese R EEC 110 60 (26–85) PFS, OS Reported 52 (5–139)
Sakaguchi 2004 [62] Japan R EC 120 32–74 OS SC 60
Saito 2006 [56] Japan P EEC 103 57 DFS, OS Reported 60 (2–148)
Salvesen 1998 [58] Norway P EC 96 65 (37–92) OS Reported 108 (60–180)
Shabani 2007 [36] Germany R EC 293 64.8 (35.5–87.9) PFS, CSS, OS SC 89.6 (3.2–135.5)
Singh 2007 [37] USA P EC 49 OS Reported 19
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Table 1 Summary table of the meta-analysis (Continued)
Sivridis 2001 [38] Greece R EC 164 – OS SC 55 (19–167)
Song 2012 [29] Korea R EC 137 53.7 (30–82) OS Reported 60
Steiner 2003 [63] Germany R EC 115 65 (38–81) OS, RFS SC 72 (36–156)
Sutton 1989 [64] USA R EC 139 61 (31–89) DFS SC, DE 28.9 (1–128)
Voss 2011 [22] England P EC 156 68.2 (37–89) DSS, RFS Reported 48.1 (0.1–141.5)
Zannoni 2013 [25] Italy P EEC 121 59 (35–88) DFS, OS Reported 38 (14–91)
Zhang 2013 [53] China R EC 239 54 (26–82) DFS, OS,
RFS
SC 67 (12–183)









Backe 1997 [54] German R EC 222 68 (30–94) OS, RFS SC 57.6 (0.24–180)
Cianciulli 2003 [76] Italy R EC 73 OS SC 72
Coronado 2001 [72] Spain R EC 114 65 (37–85) PFS SC 6 (14–107)
Gates 2006 [52] USA R EC 99 64.2 (27–95) OS report 60
Gonzalez-Rodilla
2013 [20]
Spain R EC 126 65.9 (43–88) OS report 70
Jongen 2009-2 [33] Netherlands P EEC 315 64.7 (32–89) OS, RFS Reported 59.6 (0–258)
Kohlberger 1996 [73] Australia R EC 100 64 (36–85) OS SC 140
Konecny 2009 [68] USA R EC 273 65 (38–90) OS SC EEA83 (0.3–270)
USPC20 (0.1–162),
CCC38 (0.2–180)
Mori 2010 [67] Japan R EEC 63 57.5 (32–78) RFS, OS SC 61.9 (7–133)
Odicino 2008 [69] Italy R USPC 10 positive: 79–84;
negative: 57–76
OS DE 19.7 (1–87)
Peiro 2004 [76] German R EC 10 60 (29–91) OS SC, reported 53
Saffari 1995 [74] Hispanic R EC 75 60 (29–87) OS SC 144
Santin 2005-1 [70] USA R USPC 27 66 (62–75) DSS, OS SC, reported 33 (10–48)
Santin 2005-2 [71] USA R USPC 30 67.5 (63–75) OS SC 42 (10–51)
Togami 2012 [66] Japan R UPSC 71 63.6 (47–81) RFS, OS Reported 49.7 (4–125)
Voss 2011 [22] England P EC 156 68.2 (37–89) DSS, RFS Reported 48.12 (0.12–141.48)
Study design is described as prospective (P) or retrospective (R)
EC endometrial cancer, EEC endometrioid endometrial cancer, UPSC uterine papillary serous carcinoma, OS overall survival, CSS cancer-specific survival,
DSS disease-specific survival, PFS progression-free survival, RFS relapse-free survival, DFS disease-free survival, DE data-extrapolated, SC survival curve
−not reported
[ ]Reference number
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and the USA.
A test of heterogeneity of combined HRs was conducted
using Cochran Q test and Higgins I-squared statistic. A
P value of less than 0.05 was considered significant. A
random-effect model (Der Simonian and Laird method)
was used if heterogeneity was observed (P < 0.05), whereas
the fixed-effect model was applied in the absence of
between-study heterogeneity (P < 0.05). Publication bias
was evaluated using the funnel plot with the Egger bias
indicator test. For studies assessing EC, there mostly
appeared to have heterogeneity between studies for ER,
PR, and HER2 (P < 0.05). Hence, a random model wasapplied to calculate a pooled HR and its 95 % CI. Higher
levels of either ER or PR could significantly indicate better
survival. The pooled HRs of ER for OS, CSS, and PFS
were 0.75 (95 % CI, 0.68–0.83), 0.45 (95 % CI, 0.33–0.62),
and 0.66 (95 % CI, 0.52–0.85), respectively (Fig. 2a–c).
The combined HRs of PR for OS, CSS, and PFS reached
0.63 (95 % CI, 0.56–0.71), 0.62 (95 % CI, 0.42–0.93), and
0.45 (95 % CI, 0.30–0.68), respectively (Fig. 2d–f ). In
contrast, elevated levels of HER2 could predict worse
outcome with a HR of 1.98 (95 % CI, 1.49–2.62) for OS,
and a HR of 2.26 (95 % CI, 1.57–3.25) for PFS (Fig. 2g, h).
Such results indicated that in patients with EC, higher
level of ER and PR predicted favorable survival, and
Fig. 2 Forrest plots and meta-analysis of studies evaluating hazard ratios of high hormone receptor levels as compared to low levels in EC
patients. A test of heterogeneity of combined HRs was conducted using Cochran Q test and Higgins I-squared statistic. Plots are arranged as
follows: a ER OS, b ER CSS, c ER PFS, d PR OS, e PR CSS, f PR PFS, g HER2 OS, and h HER2 PFS
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Zhang et al. World Journal of Surgical Oncology  (2015) 13:208 Page 8 of 12increased level of HER2 was associated with poorer sur-
vival. All of the three hormone receptors had prognostic
value for survival. Then, publication bias of the ERs and
PRs studies were evaluated by funnel plots and Egger tests
as shown in Table 2.
Previous studies reported that two distinct recep-
tors(ER-α and ER-β) may exert opposite effects on
cellular processes that include proliferation, apoptosis,
and migration, and their different effects may depend
on tumor type and disease stage [77]. Considering
that the different subtypes of ER and PR may haveTable 2 Comparison of the predicting value of ER-α, ER-β, PR-A,
and PR-B in EC patients
OS CSS PFS




Model Fixed Random Fixed
Bias, P value 0.379 0.968 0.975
N 1568 1332 1119
Study 7 5 6




Model Fixed – Fixed
Bias, P value 0.771 – 0.287
N 925 – 925
Study 4 – 4




Model Fixed – Fixed
Bias, P value 0.026 – 0.652
N 1038 – 696
Study 5 – 3




Model Random – Random
Bias, P value 0.748 – 0.32
N 696 – 696
Study 3 – 3
A test of heterogeneity of combined HRs was conducted using Cochran Q test
and Higgins I-squared statistic. A random-effect model (Der Simonian and
Laird method) was used if heterogeneity was observed (P < 0.05), whereas the
fixed-effect model was applied in the absence of between-study heterogeneity
(P < 0.05). Publication bias was evaluated using the funnel plot with the Egger
bias indicator test
EC endometrial cancer, ER-α estrogen receptor-alpha, ER-β estrogen receptor-
beta, PR-A progesterone receptor-A, PR-B progesterone receptor-B, HR hazards
ratio, OS overall survival, CSS cancer-specific survival, DSS disease-specific
survival, PFS progression-free survival, DFS disease-free survival,
RFS relapse-free survivaldifferent effects on cancer survival, we identified that
the studies focusing on ER-α, ER-β, PR-A, and PR-B
performed a meta-analysis. The pooled HRs of ER-α
for OS, CSS, and PFS were 0.73 (95 % CI, 0.52–1.03),
0.54 (95 % CI, 0.30–0.98), 0.84 (95 % CI, 0.57–1.24),
respectively. The combined HRs of ER-β for OS and
PFS were 0.90 (95 % CI, 0.45–1.80) and 0.84 (95 %
CI, 0.49–1.44). The pooled HRs of PR-A for OS and
PFS were 1.00 (95 % CI, 0.99–1.00) and 0.78 (95 %
CI, 0.18–3.44). The combined HRs of PR-B for OS
and PFS were 0.67 (95 % CI, 0.49–0.90) and 0.60
(95 % CI, 0.43–0.82). The results are summarized in
Table 2.
The pathogenetic role and prognostic value of HER2
in EC, especially in uterine papillary serous carcinomas
[78], one of the most malignant histological types of EC,
have recently become the focus of several studies, pro-
viding the molecular basis for targeted immunotherapy
against the highly aggressive tumors [66, 69, 79–84].
Then we tried to identify the studies focusing on uterine
papillary serous carcinoma (UPSC) and performed a
meta-analysis. Although there were only four studies
(n = 138) that could be included in this subgroup
meta-analysis, the pooled HR was 2.41 with 95 % CI
from 1.54 to 3.76 (P < 0.05) for OS [66, 69–71]
(Fig. 3). The HR was significant, and it was poten-
tially strong as a HR of an empirical cutoff for strong
predictor [84].
Conclusions
This meta-analysis indicated that hormone receptors
may have value in predicting survival in patients with
endometrial cancer. The higher levels of ER and PR were
significantly associated with favorable survival, whereas
the increased level of HER2 predicted poorer survival.
All of the three hormone receptors had prognostic value
for survival. ER and PR expression are used to identify
endometrial cancer (EC) patients that could benefit of
hormone therapy, and there are many evidences suggest-
ing that they can be good biomarkers predicting
hormone therapy response, but further validation will be
required before they are incorporated in routine man-
agement of EC patients.
However, this meta-analysis has several limitations and
the conclusions should be tempered. First, marked
heterogeneity of subjects existed in distinct groups. The
heterogeneity of the population was probably due to the
difference in the baseline characteristics of patients (age,
tumor stage, race, methodology for assessing HRs
expression, or country), the cutoff value of markers, the
undergoing treatment, the duration of follow-up, and
others. To minimize the residual confounding effect
caused by the heterogeneity within these studies, a
random-effect model was applied. Furthermore, publication
Fig. 3 Forrest plots and meta-analysis of studies evaluating hazard ratios of HER2 levels as compared to low levels about OS in UPSC patients.
A test of heterogeneity of combined HRs was conducted using Cochran Q test and Higgins I-squared statistic
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cannot be adequately overcome by currently available
statistical techniques. In addition, although the result of
UPSC subgroup about HER2 was promising, the
conclusion should be tempered for the relatively small
sample size.
Steroid hormones, including ovarian steroid hor-
mones progesterone and estrogen, play vital roles in
the development of benign endometrium and endo-
metrial cancer via their receptors [85]. Estrogens act
as a promoter of growth and proliferation of the
endometrium via estrogen receptors, while progester-
one acts as an estrogen antagonist in endometrial
maturation and inhibition of proliferation [86]. The
endometrium is very sensitive to sex hormones, and
thus a shift in the balance of estrogens and progester-
one can cause the development of endometrial cancer
[1]. The glandular epithelium from which the cancer
arises is hormone responsive, expressing both PRs
(PR-A and PR-B) and ERs (ER-α and ER-β) [87].
EC often develops from endometrial hyperplasia, which
is attributed to prolonged exposure to estrogen in the ab-
sence of (unopposed) sufficient progesterone [88], and is
often well differentiated and non-invasive or superficially
myoinvasive, rarely producing metastases and expressing
ER [89]. Whereas early-stage, well differentiated EC usu-
ally retain expression of both receptors, advanced stage,
poorly differentiated tumors often lack one or both of
these receptors, which has been correlated in many stud-
ies with a poor prognosis [19, 47]. In our meta-analysis,
both ER and PR tend to be linked with favorable outcome
of endometrial cancer and could be applied as a significant
predictor. Our results were consistent with most of the
previous basic studies that suggested the protective role of
PR in endometrial cancer.
Estrogens stimulate cell proliferation through the
classical estrogen receptors ER-α and ER-β. ER-α andER-β have a distinct pattern of expression in the tis-
sues [90], which varies during cellular proliferation
and differentiation [91]. Usually ER-α was the domin-
ant isoform in specimens of normal and diseased
endometrium [92, 93]. Some recent studies revealed that
ER-α was associated with aberrant proliferation, inflam-
mation, and the development of malignancy, whereas ER-
β seemed to oppose ER-α actions on cell proliferation by
modulating the expression of many ER-α-regulated genes
and exhibits anti-migratory and anti-invasive properties in
cancer cells [77]. In large cohorts of EC patients, ER-α
was related to early stage, lower-grade tumors [17, 33],
whereas ER-β was related to late stage EC [94]. Our study
also conducted a meta-analysis about different ERs, but el-
evated ER-α and ER-β levels alone had no significant value
in predicting favorable survival than non-distinguished
ER. Therefore, we suggested more studies on ER-α and
ER-β in the future to further clarify the distinct role of
ERs and PRs in the development of endometrial carcin-
oma and to also help identify diagnostic or therapeutic
markers.
The single-copy PR gene uses separate promoters and
translational start sites to produce two isoforms, PR-A
and PR-B [95], which are in fact two functionally distinct
transcription factors [96] and mediate their own re-
sponse genes [95, 97–99]. Studies in mice with selective
ablation of PR isoforms revealed that PR-A is necessary
for ovulation and modulates the anti-proliferative effects
of progesterone in the uterus and that PR-B is required
for normal mammary gland development and function
[100, 101]. To date, there is no evidence of such selective
roles of PR-A and PR-B in human tissues. Clinical data
in relation to the prevalence of steroid receptor isoforms
PR-A and PR-B are scarce, and the specific mechanism
is unclear. In our current meta-analysis, elevated ER-α,
ER-β, and PR-A levels did not reach significant level ma-
jorly due to the limited study number and sample size.
Zhang et al. World Journal of Surgical Oncology  (2015) 13:208 Page 10 of 12The polled HR of PR-B was associated with better out-
come, but there were only three studies that could be in-
cluded in this subgroup meta-analysis. Further analysis
in large scale study may contribute to the understanding
of ER and PR isoforms expression in EC.
In addition, HER2 plays a crucial role in the growth of
both normal tissue and malignant tumors [11]. HER2
amplification and overexpression have been shown to
play a key role in the pathogenesis of various different
cancer types, including breast, ovarian, gastric, and
esophageal carcinomas [102].
HER2 overexpression was also found to be associated
with endocrine therapy resistance, and HER2-positive
cancer might have a worse clinical outcome [103]. Our
study has demonstrated the predictive role of elevated
HER2 level for poorer survival. Such data may indicate
the harmful role of HER2 in endometrial cancer.
In summary, both elevated level of ER and PR pre-
dicted favorable survival, and elevated level of HER2 was
associated with worse survival in endometrial cancer.
The association between hormone receptor status and
survival raises the possibility of different subsets of
3patients with endometrial cancer with different biologic
behavior and different response to treatment but similar
histology or similar clinical performance. Conventional
histological examination alone may not be enough to
guide therapy and to refine the outcome prediction. We
suggest examining ER, PR, and HER2 levels to evaluate
endometrial cancer prognosis.
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